{"id":"W4406681280","doi":"10.1016/j.kint.2024.07.010","title":"KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary","year":2025,"lang":"en","type":"article","venue":"Kidney International","topic":"Genetic and Kidney Cyst Diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":87,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"Sanofi; National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health; Ono Pharmaceutical; Gilead Sciences; Nierstichting; Servier; Otsuka Pharmaceutical; Medical Research Council; Alexion Pharmaceuticals; Vertex Pharmaceuticals; Ipsen; Maze Therapeutics; Acceleron; World Health Organization; International Society of Nephrology; Cleveland Clinic; Bayer HealthCare; GlaxoSmithKline; National Health and Medical Research Council; AstraZeneca; Danone; Janssen Pharmaceuticals; American Society of Hematology","keywords":"Guideline; Autosomal dominant polycystic kidney disease; Medicine; Executive summary; Kidney disease; Disease; Intensive care medicine; Polycystic kidney disease; Internal medicine; Clinical Practice; Pathology; Family medicine; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01165262,0.001723913,0.004266334,0.008181732,0.001191084,0.003624527,0.004576125,0.006520028,0.01548532],"category_scores_gemma":[0.04942946,0.001258813,0.006227035,0.008071558,0.001260678,0.002309916,0.002703421,0.008675305,0.01495957],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005606011,"about_ca_system_score_gemma":0.0261489,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02927621,"about_ca_topic_score_gemma":0.04294351,"domain_scores_codex":[0.9852893,0.005582637,0.003735241,0.0005113311,0.004203359,0.0006781445],"domain_scores_gemma":[0.9593074,0.00904354,0.004952357,0.0006107045,0.02470297,0.001382981],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00006405046,0.00008034157,0.0005310195,0.007396836,0.0001479977,0.000161392,0.0001440448,0.0004131737,0.0001605879,0.00209083,0.8966736,0.09213614],"study_design_scores_gemma":[0.0004357064,0.0001165694,0.003961018,0.05292357,0.0005875127,0.0007292632,0.000188075,0.0005614529,0.000201476,0.005525807,0.934674,0.00009550602],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"other","genre_scores_codex":[0.002821009,0.3488796,0.03927416,0.3196452,0.03037316,0.02390471,0.08923986,0.002967084,0.1428952],"genre_scores_gemma":[0.01388597,0.4123585,0.1958886,0.120605,0.010188,0.03105939,0.1608341,0.00105687,0.05412364],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.02927621,"threshold_uncertainty_score":0.06162566,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02214863458574915,"score_gpt":0.3719724406006262,"score_spread":0.349823806014877,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}